Enliven Therapeutics, Inc. Quarterly Return On Equity in % from Q4 2019 to Q2 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Enliven Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from Q4 2019 to Q2 2024.
  • Enliven Therapeutics, Inc. Return On Equity for the quarter ending June 30, 2024 was -29.3 %, a 39.5% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Return On Equity for 2023 was -26.6 %, a 145% decline from 2022.
  • Enliven Therapeutics, Inc. annual Return On Equity for 2022 was 59.3 %.
  • Enliven Therapeutics, Inc. annual Return On Equity for 2021 was -50.2 %, a 13.2% increase from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q2 2024 -29.3 +19.2 +39.5% Apr 1, 2024 Jun 30, 2024
Q1 2024 -28.8 +170 +85.5% Jan 1, 2024 Mar 31, 2024
Q4 2023 -26.6 -85.8 -145% Oct 1, 2023 Dec 31, 2023
Q3 2023 -32.7 -61.4 -214% Jul 1, 2023 Sep 30, 2023
Q2 2023 -48.5 -191 -134% Apr 1, 2023 Jun 30, 2023
Q1 2023 -199 -68.5 -52.4% Jan 1, 2023 Mar 31, 2023
Q4 2022 59.3 +109 Oct 1, 2022 Dec 31, 2022
Q3 2022 28.7 +117 Jul 1, 2022 Sep 30, 2022
Q2 2022 143 +231 Apr 1, 2022 Jun 30, 2022
Q1 2022 -131 -61.4 -88.6% Jan 1, 2022 Mar 31, 2022
Q4 2021 -50.2 +7.65 +13.2% Oct 1, 2021 Dec 31, 2021
Q3 2021 -88.5 -30.8 -53.5% Jul 1, 2021 Sep 30, 2021
Q2 2021 -88.1 +15.5 +15% Apr 1, 2021 Jun 30, 2021
Q1 2021 -69.3 -570 -114% Jan 1, 2021 Mar 31, 2021
Q4 2020 -57.9 -118 -197% Oct 1, 2020 Dec 31, 2020
Q3 2020 -57.7 Jul 1, 2020 Sep 30, 2020
Q2 2020 -104 Apr 1, 2020 Jun 30, 2020
Q1 2020 501 Jan 1, 2020 Mar 31, 2020
Q4 2019 59.9 Oct 1, 2019 Dec 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.